1978
DOI: 10.1210/endo-103-2-554
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Synthetic vasoactive intestinal polypeptide (VIP) administered either intraventricularly or iv caused a significant and dose-related increase in plasma PRL levels in urethane-anesthetized rats. The administration of naloxone, an opiate receptor antagonist, significantly blunted the plasma PRL response to VIP. Increases in plasma PRL induced by VIP were also significantly suppressed by L-dopa, a precursor of dopamine, whereas pilocarpine, a cholinergic agonist, diphenhydramine, a histamine antagonist, and cypro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
102
0
1

Year Published

1980
1980
2000
2000

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 321 publications
(106 citation statements)
references
References 26 publications
3
102
0
1
Order By: Relevance
“…Failure of NMDA to stimulate PRL secretion after blockade of dopaminergic receptors with domperidone suggests that, in the absence of dopaminergic inhibition, the stimulatory effect of PRFs were masked and further increases in serum PRL concentrations could not be detected. Alternatively, the effects of PRFs might require a certain degree of dopaminergic inhibition, as the stimulatory effects of serotonin, thyrotrophin-releasing hormone or vasoactive intestinal polypeptide on PRL release were not detected in absence of dopaminergic inhibition (27)(28)(29)(30).…”
Section: Discussionmentioning
confidence: 99%
“…Failure of NMDA to stimulate PRL secretion after blockade of dopaminergic receptors with domperidone suggests that, in the absence of dopaminergic inhibition, the stimulatory effect of PRFs were masked and further increases in serum PRL concentrations could not be detected. Alternatively, the effects of PRFs might require a certain degree of dopaminergic inhibition, as the stimulatory effects of serotonin, thyrotrophin-releasing hormone or vasoactive intestinal polypeptide on PRL release were not detected in absence of dopaminergic inhibition (27)(28)(29)(30).…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, rats deprived of hypothalamic inputs to the pituitary exhibit a G H response to the peptide (7). In vitro, T R H triggers release of all three hormones (5,7, 10) in a perfusion system, whereas VIP is effective in vivo as well as in vitro in stimulating G H (9), PRL (10,11,17) and TSH (although weakly) (12). This evidence suggests a direct action of both neuropeptides on the three corresponding cell types.…”
Section: Discussionmentioning
confidence: 95%
“…PHI has 13 amino acids in identical positions to those in vasoactive intestinal polypeptide (VIP) and is a newly identified member of the glucagon-secretion family (Takemoto and Mutt 1981). VIP is known to cause release of PRL from the anterior pituitary both in vivo (Kato et al, 1978) and in vitro (Ruberg et al, 1978), and PHI was also reported to cause release of PRL in vitro (Werner et al, 1983). VIP was also found to induce LH-RH release from hypothalamic synaptosomes (Samson et al, 1980) and LH release from the pituitary in vivo (Vijayan et al, 1979) .…”
Section: Resultsmentioning
confidence: 99%